Valeur prédictive de la surexpression/ amplification de Her2/neu pour un traitement ciblé du cancer du sein [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer]

Details

Serval ID
serval:BIB_673CBD1DE039
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Valeur prédictive de la surexpression/ amplification de Her2/neu pour un traitement ciblé du cancer du sein [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer]
Journal
Revue Médicale Suisse
Author(s)
Lehr H.A., Schaefer S.C., Delaloye J.F.
ISSN
1660-9379
Publication state
Published
Issued date
2009
Volume
5
Number
211
Pages
1525-1529
Language
french
Abstract
Her2/neu is a tyrosine kinase receptor which stimulates cell growth. The receptor is overexpressed in about 20% of breast cancers. Her2/neu expression is an indicator of poor prognosis but also the target of the treatment of breast cancer using humanised anti-Her2/ neu antibodies. Only cancers overexpressing the protein will respond to this therapy, but which has significant (cardiac) side effects and is expensive. It is therefore important to test for the overexpression of the protein on breast cancer cells. This paper discusses how this can be done and ongoing research into new therapeutic options targeting the involved signaling pathways.
Keywords
Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Receptor, erbB-2/antagonists & inhibitors, Receptor, erbB-2/metabolism
Pubmed
Create date
01/10/2009 9:35
Last modification date
20/08/2019 14:22
Usage data